First Analysis of RSV Prevention on Infant Hospitalization Rates: So Far, So Good

Antenatal RSV vaccination in pregnant women and neonatal nirsevimab in their babies decreased infant hospitalizations.

The 2024–2025 respiratory syncytial virus (RSV) season represents the first time when effective RSV prevention strategies for both mother and child — third-trimester vaccination for pregnant women and nirsevimab for their infants — were widely available in the U.S. Has this made a difference?

Patton et al. compared rates of pediatric RSV-associated hospitalization during the 2024–2025 RSV season with two pooled seasons spanning 2018–2020. They found that during the 2024–2025 season:

RSV-hospitalized children were older than in prior seasons (~14 months compared with ~6 months).
Fewer infants aged 0–7 months were hospitalized than in prior seasons (28%–43% rate reduction), with the greatest reduction in infants less than 2 months old.
Children a…

Reviewing Author

Deborah Lehman, MD

Disclosures

Nothing to disclose

Deborah Lehman, MD

Disclosures

Nothing to disclose

First Analysis of RSV Prevention on Infant Hospitalization Rates: So Far, So Good

Topics

Reviewing Author